Results 111 to 120 of about 122,325 (212)

Hepatitis C Virus and Type 2 Diabetes: Mechanisms, Clinical Impact, and Post-DAA Management. [PDF]

J Med Virol
Chang SS, Liu CH, Chan SY, Lin LT.
europepmc   +1 more source

Impact of Treatment Response to Anticoagulant Therapy on Liver‐Related Events in Patients With Cirrhosis and Portal Vein Thrombosis

Hepatology Research, EarlyView.
In patients with cirrhosis and a first portal vein thrombosis treated with intravenous anticoagulant therapy, the 3‐year cumulative rates of liver‐related events were 56.7% and 75.5% in the effective and ineffective groups, respectively. A good radiological response was associated with fewer liver‐related hospitalizations.
Atsushi Maeda, Yuki Tahata, Hayato Hikita, Hisashi Ishida, Takayuki Yakushijin, Masanori Nakahara, Kazuyoshi Ohkawa, Fumihiko Nakanishi, Sadaharu Iio, Ryotaro Sakamori, Mitsuru Sakakibara, Masanori Miyazaki, Yuta Myoin, Kazuki Maesaka, Kumiko Shirai, Kazuhiro Murai, Yuki Makino, Yoshinobu Saito, Takahiro Kodama, Tetsuo Takehara   +19 more
wiley   +1 more source

Development of a Rapid Automated Point-of-Care Test for Hepatitis C Viral RNA on the DASH Rapid Polymerase Chain Reaction System. [PDF]

J Infect Dis
Reed JL, Butzler MA, Hawkins CA, Manabe YC, Holden J, Thomas DL, Cox AL, McFall SM.   +7 more
europepmc   +1 more source

Safety and Effectiveness of Glecaprevir/Pibrentasvir in Children and Adolescents With Chronic Hepatitis C: Reports From All‐Case Post‐Marketing Surveillance in Japan

Hepatology Research, EarlyView.
ABSTRACT Aim The aim of this all‐case post‐marketing study was to evaluate the real‐world safety and effectiveness in all children and adolescents with chronic hepatitis C with or without compensated cirrhosis treated with glecaprevir/pibrentasvir (G/P) in Japan. Methods This prospective, observational post‐marketing surveillance study was conducted at
Tatsuki Mizuochi, Katsuyoshi Kawana, Mariko Kobayashi, Eri Iwashita, Itaru Iwama, Daiki Abukawa, Hitoshi Tajiri   +6 more
wiley   +1 more source

Hepatitis Free Hospital: Retrospective Results of an In-Hospital Project of Hepatitis C Virus Micro-Elimination. [PDF]

Viruses
Cerini F, Kondili LA, Masellis C, Cosenza A, Selvaggio C, Rumi MG.   +5 more
europepmc   +1 more source

Updated Burden and Long‐Term Projections of Chronic Hepatitis B and C in Japan: A Nationwide Markov Modeling Study

Hepatology Research, EarlyView.
ABSTRACT Aim Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections remain major causes of liver‐related morbidity and mortality worldwide. Although Japan has implemented nationwide screening and treatment programs for decades, updated nationwide estimates and long‐term projections are limited.
Junko Tanaka, Akemi Kurisu, Ko Ko, Aya Sugiyama, Tomoyuki Akita   +4 more
wiley   +1 more source

Implementation of a Hepatitis C Screening Program for At-Risk Former Soviet-Bloc Immigrants in a Large Health Maintenance Organization. [PDF]

Open Forum Infect Dis
Rahamim-Cohen D, Cohen B, Atias D, Nakhleh A, Liran O, Kaplan Lavi I, Azuri J, Adler L, Ben David SS.   +8 more
europepmc   +1 more source

Olaparib‐associated cutaneous vasculitis in a patient with breast cancer

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Marcial Álvarez‐Salafranca, Teresa Puértolas, Adrián Diago, María Carmen Gómez‐Mateo   +3 more
wiley   +1 more source

Preventive Effect of Mineralocorticoid Receptor Antagonists Against Proteinuria Induced by Atezolizumab Plus Bevacizumab Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study

Hepatology Research, EarlyView.
Mineralocorticoid receptor antagonists are known to reduce proteinuria in chronic kidney disease, but their effectiveness in preventing bevacizumab‐related proteinuria has not been well established. In the present multi‐institutional retrospective study, we found that these agents significantly delay the onset of moderate or higher grade proteinuria ...
Tomoki Hori, Kazuhiro Yamamoto, Hiroshi Aoi, Yusuke Koizumi, Makoto Kuromatsu, Aiko Fukui, Hiroyo Okamoto, Atsushi Hirata, Kentaro Shinmori, Yuki Imanaka, Miyu Namba, Keisuke Nakanishi, Syunsuke Kitamura, Hideo Tsushima, Ikuko Yano, Kei Moriya, Masaru Matsui, Shigeki Ikushima   +17 more
wiley   +1 more source

Metagenomic profiling of gut microbiome signatures across liver disease stages and HCV-related hepatocellular carcinoma in Egyptian patients. [PDF]

Front Microbiol
Zahra M, Ouf A, Azzazy HME, Moustafa A.
europepmc   +1 more source